Compare JD.Com Inc (JD) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JD.Com Inc vs Tango Therapeutics Inc. — how do they compare? JD.Com Inc trades at $26.75 (market cap $36.51B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: JD.Com Inc is far larger — about 9.7× Tango Therapeutics Inc.'s market cap, and JD.Com Inc pays a 3.73% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold JD.Com Inc for 86 Days and Tango Therapeutics Inc. for 0 Days on average.
| JD | TNGX | |
|---|---|---|
Market Cap | $36.51B | $3.75B |
Volume | 8,583,924 | 9,619,106 |
Sector | Consumer Cyclical | Health |
52-Week High | $34.53 | $32.90 |
52-Week Low | $25.19 | $7.50 |
Typical Hold Time | 86 Days | 0 Days |
Enterprise Value | $19.13B | $2.77B |
Dividend Yield | 3.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JD.com trades at $26.78, up 0.22% on the day, with a bearish technical signal from moving averages but neutral oscillators. Recent earnings have consistently beaten estimates, with Q2 2026 EPS of $0.93 surpassing the $0.86 forecast. Revenue for 2025 reached $1.31 trillion, though net income margin compressed to 1.13%. The company is pursuing growth via acquisitions, such as the pending $2.5 billion Ceconomy deal, which recently gained EU approval momentum (Reuters, 2026-10-02).
The stock appears undervalued with a P/E of 17.78 and P/S of 0.2, well below sector averages. Analyst consensus is strongly bullish with a $35.38 price target, implying ~32% upside. Key risks include regulatory scrutiny in China and Europe, volatile cash flows, and competitive pressures. The robust balance sheet with $234 billion cash provides a margin of safety, but investors must weigh growth initiatives against macroeconomic headwinds.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
